Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 10:17 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 79,211 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: 2 Clear all
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

The PATHway Study: Primary Care Based Depression Prevention in Adolescents

NCT05203198
View directory record Official record
Conditions
Depression, Mental Disorder in Adolescence
Interventions
Competent Adulthood Transition with Cognitive-Behavioral, Humanistic and Interpersonal Training
Behavioral
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
13 Years to 18 Years
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
6
States / cities
Chicago, Illinois • Glenview, Illinois • Park Ridge, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 28, 2026, 10:17 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Muscle Accrual and Function in Cystic Fibrosis-Impact of Glucose Intolerance

NCT02776098
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
12 Years and older
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2024
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 7, 2024 · Synced Oct 28, 2026, 10:17 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Ketamine in the Treatment of Depression

NCT01558063
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Ketamine, Saline, Magnetic Resonance Imaging (MRI)
Drug · Procedure
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 10, 2019 · Synced Oct 28, 2026, 10:17 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor

NCT06105021
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Cancer, Colorectal Cancer, Solid Tumor, KRAS G12V
Interventions
AFNT-211
Drug
Lead sponsor
Affini-T Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
10
States / cities
Los Angeles, California • New Haven, Connecticut • New York, New York + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2025 · Synced Oct 28, 2026, 10:17 AM EDT
Completed Phase 3 Interventional Results available

Phase IIIB Subcutaneous Abatacept Monotherapy Study

NCT00547521
View directory record Official record
Conditions
Rheumatoid Arthritis (RA)
Interventions
abatacept, Methotrexate (MTX)
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
15
States / cities
Huntsville, Alabama • Mobile, Alabama • Palo Alto, California + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2015 · Synced Oct 28, 2026, 10:17 AM EDT
Completed Phase 2 Interventional Results available

A Study of Ramucirumab or Icrucumab in Colorectal Cancer

NCT01111604
View directory record Official record
Conditions
Colon Cancer, Rectal Cancer
Interventions
Ramucirumab, Icrucumab, mFOLFOX-6
Biological · Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
3
States / cities
Cincinnati, Ohio • Columbia, South Carolina • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 6, 2019 · Synced Oct 28, 2026, 10:17 AM EDT
Recruiting Phase 3 Interventional

Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children With Homozygous Familial Hypercholesterolemia

NCT06597006
View directory record Official record
Conditions
Familial Hypercholesterolemia - Homozygous
Interventions
Inclisiran, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
2 Years to 11 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
4
States / cities
San Francisco, California • Washington D.C., District of Columbia • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 28, 2026, 10:17 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Accuracy Validation of Belun Oxygen Saturation Pulse Oximeter FDA Submission Study

NCT03439306
View directory record Official record
Conditions
Hypoxia
Interventions
Pulse Oximeter
Device
Lead sponsor
Belun Technology Company Limited
Other
Eligibility
18 Years to 50 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Louisville, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 20, 2018 · Synced Oct 28, 2026, 10:17 AM EDT
Completed Phase 2 Interventional Results available

Memantine for Prevention of Cognitive Late Effects in Pediatric Patients Receiving Cranial Radiation Therapy for Localized Brain Tumors

NCT03194906
View directory record Official record
Conditions
Glioma of Brain, Craniopharyngioma, Ependymoma, Germ Cell Tumor
Interventions
Memantine, Placebo, Cognitive Assessment
Drug · Other
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
6 Years to 21 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 28, 2026, 10:17 AM EDT
Completed Not applicable Interventional

Metabolic Response to 3-day Fast Versus Carbohydrate-free Diet in Type 2 Diabetes

NCT01469104
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
3 day fast, 3 day CHO-free diet
Other
Lead sponsor
Minneapolis Veterans Affairs Medical Center
Federal
Eligibility
45 Years to 75 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 10, 2011 · Synced Oct 28, 2026, 10:17 AM EDT
Completed Phase 4 Interventional Results available

Loss of Resistance, w/wo Stimulation, For Epidural Placement

NCT03087604
View directory record Official record
Conditions
Anesthesia
Interventions
Thoracic epidural block, Electrical Nerve stimulation, Solution For Thoracic epidural block
Procedure · Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 90 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 17, 2020 · Synced Oct 28, 2026, 10:17 AM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

A First in Human Study of CMND-100 in Healthy and Alcohol Use Disorder (AUD) Subjects

NCT05913752
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
CMND-100
Drug
Lead sponsor
Clearmind Medicine Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
2
States / cities
New Haven, Connecticut • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Oct 28, 2026, 10:17 AM EDT
Completed Phase 1Phase 2 Interventional Results available

AMD3100 Plus Mitoxantrone, Etoposide and Cytarabine in Acute Myeloid Leukemia

NCT00512252
View directory record Official record
Conditions
Leukemia, Myeloid, Acute
Interventions
AMD3100, Mitoxantrone, Etoposide, Cytarabine
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 70 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 12, 2016 · Synced Oct 28, 2026, 10:17 AM EDT
Terminated Phase 2 Interventional Results available

Study Evaluating the Safety and Effects of MN-221 in Subjects Experiencing an Acute Exacerbation of Asthma

NCT00683449
View directory record Official record
Conditions
Asthma, Status Asthmaticus
Interventions
Dose Group 1, MN-221 placebo, Dose Group 2, Dose Group 3
Drug
Lead sponsor
MediciNova
Industry
Eligibility
18 Years to 55 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
9
States / cities
Phoenix, Arizona • Los Angeles, California • Sylmar, California + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2011 · Synced Oct 28, 2026, 10:17 AM EDT
Active, not recruiting Phase 1 Interventional Results available

Testing the Addition of the Anti-cancer Viral Therapy Telomelysin™ to Chemoradiation for Patients With Advanced Esophageal Cancer and Are Not Candidates for Surgery

NCT04391049
View directory record Official record
Conditions
Advanced Esophageal Adenocarcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8, Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IIB Esophageal Adenocarcinoma AJCC v8, Clinical Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage II Esophageal Adenocarcinoma AJCC v8, Pathologic Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIA Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage III Esophageal Adenocarcinoma AJCC v8, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage II Esophageal Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage III Esophageal Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIA Esophageal Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIB Esophageal Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Unresectable Gastroesophageal Junction Adenocarcinoma, Squamous Cell Carcinoma, Squamous Cell Cancer
Interventions
Carboplatin, Paclitaxel, Radiation Therapy, Telomerase-specific Type 5 Adenovirus OBP-301
Drug · Radiation · Biological
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
17
States / cities
Duarte, California • South Pasadena, California • Upland, California + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 28, 2026, 10:17 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Vorinostat and Trastuzumab in Treating Patients With Metastatic or Locally Recurrent Breast Cancer

NCT00258349
View directory record Official record
Conditions
Breast Cancer, Male Breast Cancer, Recurrent Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
Interventions
vorinostat, trastuzumab
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
25
States / cities
Birmingham, Alabama • Des Moines, Iowa • Sioux City, Iowa + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2014 · Synced Oct 28, 2026, 10:17 AM EDT
Completed No phase listed Observational

A Phased-Implementation Feasibility and Proof-of-Concept Study to Assess Incorporating the NIDA CTN Common Data Elements (CDEs) Into the Electronic Health Record (EHR) in Large Primary Care Settings ("CDE-EHR-PC" Study), Phase 3

NCT02963948
View directory record Official record
Conditions
Substance Abuse
Interventions
Meetings with implementation leader(s), the SAAS survey, Patient surveys
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
113,123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
2
States / cities
Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 29, 2022 · Synced Oct 28, 2026, 10:17 AM EDT
Completed Phase 1 Interventional

A Phase 1/2 Study of MEDI4276 in Adults Subjects With Select HER2-expressing Advanced Solid Tumors.

NCT02576548
View directory record Official record
Conditions
HER2 Expressing Breast or Gastric/Stomach Cancers
Interventions
MEDI4276
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
5
States / cities
Stanford, California • Sarasota, Florida • Indianapolis, Indiana + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2019 · Synced Oct 28, 2026, 10:17 AM EDT
Active, not recruiting Phase 2 Interventional

Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients With aDvanced Human Epidermal Growth Factor Receptor 2+ brEast Cancer With the Addition of Tucatinib

NCT05323955
View directory record Official record
Conditions
Brain Metastases, Human Epidermal Growth Factor 2 Positive Carcinoma of Breast, Advanced Breast Cancer
Interventions
Trastuzumab, Trastuzumab Emtansine (T-DM1), Pertuzumab, Tucatinib
Drug
Lead sponsor
Carey Anders, M.D.
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
8
States / cities
San Francisco, California • Boston, Massachusetts • Ann Arbor, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 28, 2026, 10:17 AM EDT
Not listed Phase 4 Interventional

Mechanistic Study of the Systolic Blood Pressure Lowering Effect of Dapagliflozin in Type 2 Diabetes

NCT02372955
View directory record Official record
Conditions
Diabetes Mellitus Type 2
Interventions
dapagliflozin, glimpiride
Drug
Lead sponsor
Gulf Regional Research & Educational Services, LLC
Other
Eligibility
21 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Metairie, Louisiana
Source: ClinicalTrials.gov public record
Updated Feb 26, 2015 · Synced Oct 28, 2026, 10:17 AM EDT
Recruiting Not applicable Interventional

SAINT in Postpartum Depression (PPD)

NCT07210255
View directory record Official record
Conditions
Postpartum Depression (PPD)
Interventions
SAINT Neuromodulation System, Sham SAINT Stimulation
Device
Lead sponsor
Magnus Medical
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
4
States / cities
Worcester, Massachusetts • New York, New York • Charleston, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 28, 2026, 10:17 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Physiological, Behavioral and Subjective Effects of Drugs (GHB)

NCT00058955
View directory record Official record
Conditions
Sedative Abuse
Interventions
sodium oxybate, triazolam and pentobarbital
Drug
Lead sponsor
Orphan Medical
Industry
Eligibility
18 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2005
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 10, 2008 · Synced Oct 28, 2026, 10:17 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

A Study of Multiple-ascending Doses of GSBR-1290 in Healthy Overweight/Obese Participants

NCT06139055
View directory record Official record
Conditions
Healthy Volunteers
Interventions
GSBR-1290 (Capsule/Tablet), GSBR-1290, Placebo, Placebo (Capsule/Tablet)
Drug
Lead sponsor
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
3
States / cities
Miami, Florida • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 15, 2024 · Synced Oct 28, 2026, 10:17 AM EDT
Not listed Not applicable Interventional

PoNS Clinical Experience Program (TBI)

NCT03732755
View directory record Official record
Conditions
Mild to Moderate Traumatic Brain Injury
Interventions
PoNS Treatment
Device
Lead sponsor
Helius Medical Inc
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
West Orange, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 20, 2019 · Synced Oct 28, 2026, 10:17 AM EDT